Patent · US Active

Dendritic oligopeptide-grafteded cyclotriphosphazene, a process for the preparation thereof and a drug delivery system containing the same

US8344173B2 · kind B2 · utility

0Cited by
0References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 28, 2009
Grant dateJan 1, 2013
Priority date
Expiry dateJan 4, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07F9/65815
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A cyclotriphosphazene represented by Formula 1 prepared by introducing a dendritic tetrapeptide and a hydrophilic polyethylene glycol into a cyclotriphosphazene ring, a method of preparing the same, and a drug carrier including the cyclotriphosphazene of Formula 1.The compound according to the present invention may form a strong molecular hydrogel in a very low concentration of 2 w/w % or less. Furthermore, the hydrogel prepared using the compound of Formula 1 exhibits biodegradability, thermosensitivity at around body temperature, biocompatibility with protein drugs, and an easy way to prepare along with a sustained release property without any burst effect in the early stage of release. Therefore, the present cyclotriphosphazene molecular hydrogel may be efficiently used as a drug carrier for a sustained release of a drug, particularly, a protein drug.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.